

**МІНІСТЕРСТВО ОХОРОНИ ЗДОРОВ'Я УКРАЇНИ
БУКОВИНСЬКИЙ ДЕРЖАВНИЙ МЕДИЧНИЙ УНІВЕРСИТЕТ**



МАТЕРІАЛИ

**106-ї підсумкової науково-практичної конференції
з міжнародною участю
професорсько-викладацького колективу
БУКОВИНСЬКОГО ДЕРЖАВНОГО МЕДИЧНОГО УНІВЕРСИТЕТУ
03, 05, 10 лютого 2025 року**

Конференція внесена до Реєстру заходів безперервного професійного розвитку,
які проводитимуться у 2025 році №1005249

Чернівці – 2025

УДК 61(063)
М 34

Матеріали підсумкової 106-ї науково-практичної конференції з міжнародною участю професорсько-викладацького колективу Буковинського державного медичного університету (м. Чернівці, 03, 05, 10 лютого 2025 р.) – Чернівці: Медуніверситет, 2025. – 450 с. іл.

У збірнику представлені матеріали 106-ї науково-практичної конференції з міжнародною участю професорсько-викладацького колективу Буковинського державного медичного університету (м. Чернівці, 03, 05, 10 лютого 2025 р.) зі стилістикою та орфографією у авторській редакції. Публікації присвячені актуальним проблемам фундаментальної, теоретичної та клінічної медицини.

Загальна редакція: професор Геруш І.В., професорка Годованець О.І., професор Безрук В.В.

Наукові рецензенти:

професор Батіг В.М.
професор Білоокій В.В.
професор Булик Р.Є.
професор Давиденко І.С.
професор Дейнека С.Є.
професорка Денисенко О.І.
професор Заморський І.І.
професорка Колоскова О.К.
професорка Кравченко О.В.
професорка Пашковська Н.В.
професорка Ткачук С.С.
професорка Тодоріко Л.Д.
професорка Хухліна О.С.
професор Черноус В.О.

ISBN 978-617-519-135-4

© Буковинський державний медичний
університет, 2025

Matushchak M.R.

STUDY OF THE PHARMACEUTICAL COMPONENT OF THE CLINICAL PROTOCOL FOR THE TREATMENT OF PATIENTS WITH HODGKIN'S LYMPHOMA IN UKRAINE

*Department of Pharmaceutical Botany and Pharmacognosy
Bukovinian State Medical University*

Introduction. In the treatment of patients with Hodgkin's lymphoma (HL), chemotherapy (ChT) occupies one of the priority places. Therefore, the issue of effective pharmaceutical support for patients with HL is relevant and socially important.

The aim of the study. To analyze the data of the "Unified clinical protocol of primary, secondary (specialized), tertiary (highly specialized) medical care "Non-Hodgkin's lymphomas and Hodgkin's lymphoma" (order of the Ministry of Health of Ukraine № 866 of 08.10.2013 "On the approval and implementation of medical and technological documents on the standardization of medical care in non-Hodgkin's lymphomas and Hodgkin's lymphoma") to comply with the requirements of legislative and regulatory acts that regulate the circulation of medicinal products.

Material and methods. The studies used general theoretical research methods (historical, comparative, logical, etc.).

Results. According to the INN, clinical protocols and guidelines recommend the use of 14 drug names in the treatment of patients with various forms of HL, including 12 drugs (doxorubicin, bleomycin, vinblastine, dacarbazine, etoposide, cyclophosphamide, procarbazine, vincristine, ifosfamide, mitoxantrone, chlorambucil, bendamustine, mesna) which belong to the group of anticancer drugs (PPDs) that have an alkylating mechanism of action on tumor cells. It has been established that the Model List of Essential Medicines of the WHO 22nd edition (September 2021) contains all the names of PPIs, except for mitoxantrone. One drug, mesna, was also missing from the latest National List of Essential Medicines edition. In addition, this drug was also absent from the list of medicines recommended by the State Formulary of Medicines of the 14th edition for the treatment of various forms of LH. Based on the analysis of the 14th edition of the State Formulary of Medicines, we have established that in its composition ("Oncology" section), there were already three names of medicines missing in the prescription for the treatment of HL. These are vinblastine sulfate, mesna and procarbazine. Taking into account the fact that the data of the State Formulary of Medicines are of a recommendatory nature regarding the use of certain drug names, this fact cannot significantly impact the effectiveness of the organization in providing medical and pharmaceutical care to patients with HL. As you can see, almost all drugs that are recommended by clinical protocols and modern guidelines for the treatment of patients with HL are presented in legislative and regulatory documents that regulate the circulation of drugs in Ukraine.

Next, we analyzed the data of the order of the Ministry of Health dated 11.08.2021, № 1723 "On approval of the nomenclature of medicines, immunobiological preparations (vaccines), medical devices (including medical equipment) and auxiliary means for them, purchased under the budget program "Provision of medical measures of individual state programs and complex measures of a programmatic nature". The specified order contains a list of drugs used in the treatment of oncological and hematological oncological patients.

According to the data of the analysis, it was established that all the names of PPIs used in the main and additional schemes of ChT HL (diagnosis established for the first time, primary-refractory and recurrent forms) are listed in the relevant table of the order of the Ministry of Health of August 11, 2021 № 1723. These drugs can be purchased under the budget program "Provision of medical measures of certain state programs and complex program measures".

Conclusions. Thus, it can be argued that complementarity of norms and requirements presented in various legislative and regulatory acts governing the circulation of medicines in the country plays an important role in the organization of effective pharmaceutical support for patients with Hodgkin's lymphoma.